FUJIFILM Pharmaceuticals U.S.A. Inc reported on Wednesday that FUJIFILM Corporation has ramped up its manufacturing capacity at FUJIFILM Toyama Chemical Co Ltd to increase production of its influenza antiviral drug Avigan Tablet (generic name: favipiravir) for treating patients with COVID-19.
In conjunction, Fujifilm is allocating additional capacity at its Japanese FUJIFILM Wako Pure Chemical Co Ltd facility for production of pharmaceutical intermediates used in the manufacture Avigan. The company has also established partnerships with domestic and overseas companies for various manufacturing processes to source raw materials and pharmaceutical substances.
Avigan selectively inhibits viral RNA polymerase necessary for influenza virus replication. Due to this mechanism of action, Avigan may have an antiviral effect on the SARS-CoV-2 coronavirus.
Fujifilm expects to increase the monthly production of Avigan up to 100,000 treatment courses by July 2020, approximately 2.5 times more compared to the beginning of March, with production further increased to 300,000 treatment courses by September 2020.
The Japanese government reportedly plans to stockpile 2 million treatment courses of Avigan as part of its emergency economic package.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling